Earnings And Financial Performance4Q revenue would be 4% below current consensus, and 4Q EPS would be 10% below current consensus.
Future Financial OutlookLong-term EPS growth is estimated to decline, indicating potential challenges in sustained profitability.
Product Development And TrialsPfizer recently upsized and delayed ponsegromab’s Ph2 trial, including changing the estimated primary completion date from March 2025 to March 2026.